Replies to post #19407 on Positron Corporation (POSC)

[zenvesting]

I agree, cardiac PET is already gaining significant traction with the coalition of industry organizations that teamed up to defend medicare reimbursement rates for cardiac PET last year.

It looks like cardiac PET will be ready to overtake SPECT for myocardial perfusion imaging (MPI) when Flurpiridaz F-18 gets FDA approval, now expected in early 2023. Thousands of PET cameras will be needed and Positron is well positioned to benefit when that demand comes.